A shift to higher-growth systems and a tie-up with Illumina are sensible moves, but will take time to pay off.
The overall rate of device approvals in 2019 is holding steady on last year – but the types of approvals are different.
The US FDA granted seven approvals in two days last week, including an eagerly awaited thumbs-up for Novartis’s gene therapy Zolgensma.
The Swiss group has succeeded with its internally developed diagnostics, but buying in innovation has served Becton Dickinson well.
Sequencing data is all well and good, but what does it mean?
Experience and high staff levels help companies negotiate FDA approval – but luck plays a part.